|
|
|
|
Selective M3 muscarinic receptor antagonist inhibits small-cell lung carcinoma growth in a mouse orthotopic xenograft model
|
|
|
|
|
|
|
|
نویسنده
|
ami n. ,koga k. ,fushiki h. ,ueno y. ,ogino y. ,ohta h.
|
|
منبع
|
journal of pharmacological sciences - 2011 - دوره : 116 - شماره : 1 - صفحه:81 -88
|
|
چکیده
|
In small cell lung carcinoma (sclc),acetylcholine (ach) is synthesized and secreted,and it acts as an autocrine growth factor through activation of its receptors,muscarinic receptor (machr) and nicotinic receptor (nachr). alteration of tumor growth by blockade of m3 machr in a human sclc cell line,nci-h82,was investigated in the present study. we used a highly selective m3 muscarinic antagonist,n-(2-[3-([3r]-1- (cyclohexylmethyl)-3-piperidinyl]methylamino)-3-oxopropyl]amino-2-oxoethyl)-3,3,3-triphenyl-propioamide (j-115311). our results show that j-115311 inhibited the increased intracellular calcium elicited by carbachol,a muscarinic agonist,in sclc cells. j-115311 also inhibited sclc cell growth in vitro. in a mouse orthotopic xenograft model,j-115311 dose-dependently reduced tumor growth when nci-h82 cells were inoculated into the upper left lobe of the lung. these findings indicate that blockade of m3 machr can suppress tumor growth in sclc,suggesting the potential therapeutic utility of m3 muscarinic antagonists as anti-cancer agents. © the japanese pharmacological society.
|
|
کلیدواژه
|
M3 muscarinic receptor; Non-neuronal cholinergic system; Orthotopic xenograft model; Selective M3 muscarinic antagonist; Small cell lung carcinoma
|
|
آدرس
|
department of pharmacology,tsukuba research institute,banyu pharmaceutical co.,ltd.,3 ohkubo,tsukuba-shi,ibaraki 300-2611,japan,r and d center,terumo co.,1500 inokuchi,nakai-machi,ashigarakami-gun,kanagawa 259-0151, Japan, department of pharmacology,tsukuba research institute,banyu pharmaceutical co.,ltd.,3 ohkubo,tsukuba-shi,ibaraki 300-2611,japan,discovery pharmacology,taisho pharmaceutical co.,ltd.,1-403 yoshino-cho,kita-ku,saitama-shi,saitama 331-9520, Japan, department of pharmacology,tsukuba research institute,banyu pharmaceutical co.,ltd.,3 ohkubo,tsukuba-shi,ibaraki 300-2611,japan,drug discovery research,astellas pharma inc.,21 miyukigaoka,tsukuba-shi,ibaraki 305-8585, Japan, department of pharmacology,tsukuba research institute,banyu pharmaceutical co.,ltd.,3 ohkubo,tsukuba-shi,ibaraki 300-2611,japan,drug discovery research,astellas pharma inc.,21 miyukigaoka,tsukuba-shi,ibaraki 305-8585, Japan, department of pharmacology,tsukuba research institute,banyu pharmaceutical co.,ltd.,3 ohkubo,tsukuba-shi,ibaraki 300-2611,japan,tsukuba research institute,drug discovery research center,taiho pharmaceutical co.,ltd.,3 ohkubo,tsukuba-shi,ibaraki 300-2611, Japan, department of pharmacology,tsukuba research institute,banyu pharmaceutical co.,ltd.,3 ohkubo,tsukuba-shi,ibaraki 300-2611,japan,research and development center,sato pharmaceutical co.,ltd.,6-8-5 higashi-ohi,shinagawa-ku,tokyo 140-0011, Japan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|